Upadacitinib meets primary endpoints in phase III SELECT-PsA 1 study in psoriatic arthritis

In study (n=1275 who have responded inadequately or are intolerant to ≥1 non-biologic DMARDs), 71% and 79% of patients receiving 15 mg and 30 mg doses achieved ACR20 at week 12, respectively, compared to 36% of patients receiving placebo (p<0.0001).


Biospace Inc.